Arbutus Biopharma Corporation (FRA:I9DN)
Germany · Delayed Price · Currency is EUR 3.650
+0.010 (0.27%)
At close: Nov 26, 2025
Arbutus Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 14.61 | 6.17 | 18.14 | 39.02 | 10.99 | 6.91 | Upgrade | |
Revenue Growth (YoY) | 116.64% | -65.98% | -53.51% | 255.11% | 58.92% | 15.02% | Upgrade |
Cost of Revenue | 29.05 | 54.04 | 73.7 | 84.41 | 65.5 | 49.34 | Upgrade |
Gross Profit | -14.44 | -47.87 | -55.56 | -45.39 | -54.51 | -42.42 | Upgrade |
Selling, General & Admin | 16.92 | 22.11 | 22.48 | 17.83 | 17.14 | 14.85 | Upgrade |
Operating Expenses | 16.92 | 22.11 | 22.48 | 17.83 | 17.14 | 14.85 | Upgrade |
Operating Income | -31.36 | -69.97 | -78.03 | -63.22 | -71.65 | -57.27 | Upgrade |
Interest Expense | -0.11 | -0.14 | -0.46 | -1.73 | -2.86 | -4.01 | Upgrade |
Interest & Investment Income | 4.66 | 6.59 | 5.69 | 2.19 | 0.13 | 0.74 | Upgrade |
Earnings From Equity Investments | - | - | - | - | - | -2.55 | Upgrade |
Currency Exchange Gain (Loss) | -0.02 | -0.05 | 0.03 | -0.02 | 0.01 | -0.12 | Upgrade |
EBT Excluding Unusual Items | -26.83 | -63.58 | -72.78 | -62.78 | -74.38 | -63.21 | Upgrade |
Merger & Restructuring Charges | -12.73 | -3.72 | - | - | - | -0.06 | Upgrade |
Other Unusual Items | -2.72 | -2.63 | -0.07 | -2.23 | -1.87 | -0.47 | Upgrade |
Pretax Income | -42.28 | -69.92 | -72.85 | -65.01 | -76.25 | -63.75 | Upgrade |
Income Tax Expense | - | - | - | 4.44 | - | - | Upgrade |
Net Income | -42.28 | -69.92 | -72.85 | -69.46 | -76.25 | -63.75 | Upgrade |
Preferred Dividends & Other Adjustments | - | - | - | - | 12.14 | 12.12 | Upgrade |
Net Income to Common | -42.28 | -69.92 | -72.85 | -69.46 | -88.39 | -75.87 | Upgrade |
Shares Outstanding (Basic) | 191 | 186 | 166 | 151 | 106 | 76 | Upgrade |
Shares Outstanding (Diluted) | 191 | 186 | 166 | 151 | 106 | 76 | Upgrade |
Shares Change (YoY) | 5.88% | 11.84% | 9.95% | 42.07% | 40.10% | 32.83% | Upgrade |
EPS (Basic) | -0.22 | -0.38 | -0.44 | -0.46 | -0.83 | -1.00 | Upgrade |
EPS (Diluted) | -0.22 | -0.38 | -0.44 | -0.46 | -0.83 | -1.00 | Upgrade |
Free Cash Flow | -45.36 | -65.03 | -86.94 | -35.87 | -68.34 | -51.67 | Upgrade |
Free Cash Flow Per Share | -0.24 | -0.35 | -0.52 | -0.24 | -0.64 | -0.68 | Upgrade |
Gross Margin | -98.86% | - | - | -116.32% | - | - | Upgrade |
Operating Margin | -214.67% | -1133.92% | -430.15% | -162.03% | -652.07% | -828.30% | Upgrade |
Profit Margin | -289.45% | -1133.04% | -401.57% | -178.01% | -804.39% | -1097.31% | Upgrade |
Free Cash Flow Margin | -310.54% | -1053.83% | -479.27% | -91.92% | -621.96% | -747.32% | Upgrade |
EBITDA | -30.67 | -68.59 | -76.63 | -61.8 | -69.9 | -55.29 | Upgrade |
EBITDA Margin | -209.98% | - | - | -158.37% | - | - | Upgrade |
D&A For EBITDA | 0.69 | 1.38 | 1.4 | 1.43 | 1.75 | 1.98 | Upgrade |
EBIT | -31.36 | -69.97 | -78.03 | -63.22 | -71.65 | -57.27 | Upgrade |
EBIT Margin | -214.67% | - | - | -162.03% | - | - | Upgrade |
Revenue as Reported | 14.61 | 6.17 | 18.14 | 39.02 | 10.99 | 6.91 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.